论文部分内容阅读
目的:研究青芪散对免疫性肝损伤的干预作用。方法:将72只小鼠随机分成6组,除正常组外其他组造模,分别为病理组、迈普新(Tα1)组及青芪散小、中、大剂量组,每组12只。主要检测谷丙转氨酶(ALT)、谷草转氨酶(AST)等肝功能指标及观察各组组织病理学结果。结果:ALT、AST病理组与正常组比较,差异有非常显著性意义(P<0.01);各造模组与病理组比较,差异有非常显著性意义(P<0.01);青芪散中剂量组与迈普新组比较,差异有显著性意义(P<0.05)。观察各组小鼠肝脏病组织学损伤程度,病理组与正常组比较,差异有非常显著性意义(P<0.01);各造模组与病理组比较,差异有非常显著性意义(P<0.01);青芪散中剂量组与迈普新组比较,差异无显著性意义(P>0.05)。结论:青芪散中等剂量有明确的抗免疫性肝损伤作用。
Objective: To study the effect of Qinglan Powder on immune liver injury. Methods: 72 mice were randomly divided into 6 groups, except for the normal group. The models were pathological group, Maipuxin (Tα1) group and Qingdaisan small, medium and high dose group, with 12 in each group. The liver function indexes such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were detected and histopathological results were observed. Results: Compared with the normal group, pathological group of ALT and AST had significant difference (P<0.01). There was significant difference between each model group and pathological group (P<0.01). There was significant difference between the group and Maipuxin group (P<0.05). Observe the degree of histological damage of liver diseases in each group. Compared with normal group, pathological group had significant difference (P<0.01). The difference between each model group and pathological group was very significant (P<0.01). There is no significant difference between the middle-dose group and the Maipuxin group (P>0.05). Conclusion: Qingdaisan has clear anti-immune liver injury.